Field Trip's Phase I Clinical Study Of Psilocybin Analog FT-104 Begins Dosing In Australia
Developer and provider of psychedelic therapies Field Trip Health Ltd. has announced the first successful dosing of a Phase 1 clinical trial on it's proprietary psychedelic molecule.
